Pricing Log in Create free account

Rigel Pharmaceuticals, Inc. (RIGL) vs Solid Biosciences Inc. (SLDB)

Rigel Pharmaceuticals, Inc. and Solid Biosciences Inc. are both Biotechnology companies. Rigel Pharmaceuticals, Inc. and Solid Biosciences Inc. are of similar size ($848.2M and $838.3M). Solid Biosciences Inc. has negative trailing earnings, so its P/E is not meaningful; Rigel Pharmaceuticals, Inc. trades at 2.6×. Rigel Pharmaceuticals, Inc. has the higher net margin (106.6% vs 0.00%) and the higher return on invested capital (13.7% vs 0.00%). Across the 15 metrics below, Rigel Pharmaceuticals, Inc. leads on 14 and Solid Biosciences Inc. on 1.

Valuation

Metric RIGL SLDB Biotechnology median
P/E 2.64 n/m 11.58
P/S 2.88 101.91 9.61
P/B 1.87 3.35 2.26
Price to free cash flow 42.58 n/m 26.41
EV/EBITDA 9.44 n/m 0.72
EV/Sales 2.59 70.86 9.43
Earnings yield 37.87% (23.55%) (32.28%)
Free cash flow yield 2.35% (17.47%) (22.27%)

Profitability

Metric RIGL SLDB Biotechnology median
Gross margin 89.64% 0.00% 68.81%
Operating margin 26.28% 0.00% 0.00%
Net margin 106.59% 0.00% 0.00%
Free cash flow margin 6.72% 0.00% 0.00%
Return on equity 109.18% (76.87%) (50.30%)
Return on assets 80.16% (64.86%) (45.47%)
Return on invested capital 13.69% 0.00% 0.00%

Growth

Metric RIGL SLDB Biotechnology median
Revenue growth (TTM) 2.18% — 6.78%
EPS growth (last fiscal year) 1,867.68% 34.97% 29.88%
Revenue growth, 5-year CAGR 22.06% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RIGL SLDB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.39 11.99 4.74
Net debt to EBITDA (1.05) 1.05 1.01

Dividend

Metric RIGL SLDB Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric RIGL SLDB Biotechnology median
Market cap 838.31m 848.24m 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack